EZH2 and gastric cancer: Furthermore, the combination of siSTAT3 and the EZH2-specific inhibitor 3-deazaneplanocin A (DZNep) increased the apoptosis rate of GC cells, suggesting that the combination of siSTAT3 and EZH2 inhibitors may contribute to the potential epigenetic treatment of GC patients.